文献速递淋巴瘤

双特异性抗体联合治疗在弥漫性大B细胞淋巴瘤中的应用

Bispecific antibody combination therapies in diffuse large B-cell lymphoma.
PubMed 文献 · Br J Haematol · 2025-11-07

本文综述双特异性T细胞衔接抗体(TCE)在弥漫性大B细胞淋巴瘤(DLBCL)中的耐药机制与联合策略。TCE已作为三线单药及二线联合方案显示临床活性,疗效依赖靶抗原持续表达与T细胞功能保留;联合策略旨在克服耐药、增强抗肿瘤疗效并可能减少治疗相关不良事件。

要点

  • TCE在DLBCL中显示稳健临床活性且毒性可控,已进入三线单药、二线联合及一线探索。
  • TCE疗效依赖靶抗原持续表达与T细胞功能保留,任一丢失或肿瘤微环境生物学均促进耐药。
  • 联合策略旨在克服耐药机制、增强抗肿瘤疗效并可能减少治疗相关不良事件。

核心结论

  • TCE是DLBCL治疗的重要进展,联合策略旨在克服耐药并增强疗效。

研究设计与样本

  • 综述,批判性审视TCE耐药机制及基于此的联合策略,并回顾新兴临床试验结果。

主要发现

  • TCE已作为三线单药、二线联合方案显示稳健临床活性,一线数据亦显示治疗潜力。
  • TCE疗效依赖靶抗原持续表达与T细胞功能保留,任一丢失或内在肿瘤及微环境生物学促进耐药。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bispecific T-cell-engaging antibodies (TCEs) are a significant advance in the treatment of diffuse large B-cell lymphoma (DLBCL), demonstrating robust clinical activity with manageable toxicity profiles. Their integration into third line as monotherapy, and now second line in combination, as well as recent data in the first line underscores their therapeutic potential. The efficacy of bispecific antibodies depends on sustained target antigen expression and preserved T-cell function; the loss of either of these factors, or intrinsic tumour and microenvironment biology, contributes to therapeutic resistance. Combination strategies aim to overcome these resistance mechanisms, enhance anti-tumour efficacy and potentially reduce treatment-related adverse events. In this review, we critically examine the current understanding of TCE resistance and discuss how this informs combination strategies. We explore approaches to bispecific antibody-based combination therapies in DLBCL and review emerging clinical trial results, with a view on potential future strategies for TCE-based combinations.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Harrop S, Minson A, Steiner TM, et al. Bispecific antibody combination therapies in diffuse large B-cell lymphoma. Br J Haematol. 2025. PMID: 41201275. doi:10.1111/bjh.70228

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。